Literature DB >> 7881965

Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer.

P Forouhi1, J M Dixon, R C Leonard, U Chetty.   

Abstract

The influence of primary systemic therapy in treating operable breast cancer on postmastectomy morbidity rates was investigated. The contribution of other risk factors was assessed by multiple logistic regression. Seventy-nine eligible patients were randomly allocated, 39 to undergo immediate modified radical mastectomy, and 40 to receive initial cytotoxic or endocrine treatment followed by mastectomy. Postoperative wound seroma, infection and necrosis were recorded prospectively. Fourteen minor and six major complications occurred in 17 patients treated conventionally, while 14 patients developed 11 minor and six major complications after systemic therapy (P > 0.4). Median hospital stay was 8 days for both groups. Age, smoking, immediate breast reconstruction and the type of primary systemic treatment given were not independent predictors of complication risk. Obesity emerged as a significant risk factor for postmastectomy complications (P = 0.015). Primary systemic therapy does not increase the rate of morbidity after mastectomy.

Entities:  

Mesh:

Year:  1995        PMID: 7881965     DOI: 10.1002/bjs.1800820127

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

Review 1.  Breast reconstruction following prophylactic or therapeutic mastectomy for breast cancer: Recommendations from an evidence-based provincial guideline.

Authors:  Melissa Shea-Budgell; May Lynn Quan; Blair Mehling; Claire Temple-Oberle
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

2.  Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.

Authors:  Elizabeth A Mittendorf; Thomas A Buchholz; Susan L Tucker; Funda Meric-Bernstam; Henry M Kuerer; Ana M Gonzalez-Angulo; Isabelle Bedrosian; Gildy V Babiera; Karen Hoffman; Min Yi; Merrick I Ross; Gabriel N Hortobagyi; Kelly K Hunt
Journal:  Ann Surg       Date:  2013-02       Impact factor: 12.969

3.  Obesity predisposes to increased drainage following axillary node clearance: a prospective audit.

Authors:  D Banerjee; E V Williams; J Ilott; I J Monypenny; D J Webster
Journal:  Ann R Coll Surg Engl       Date:  2001-07       Impact factor: 1.891

4.  Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.

Authors:  D A Cameron; E D Anderson; P Levack; R A Hawkins; T J Anderson; R C Leonard; A P Forrest; U Chetty
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Effects of dextran-40 on flap viability after modified radical mastectomy.

Authors:  Baris Dogu Yildiz; Barlas Sulu
Journal:  Can J Plast Surg       Date:  2013

6.  Impact of different type of cancer treatment on the effectiveness of breast reconstruction.

Authors:  Joanna Szloch; Elżbieta Marczyk; Marta Kołodziej-Rzepa; Andrzej L Komorowski
Journal:  Gland Surg       Date:  2016-08

Review 7.  Combination of physical activity, nutrition, or other metabolic factors and vaccine response.

Authors:  Kenneth W Hance; Connie J Rogers; Stephen D Hursting; John W Greiner
Journal:  Front Biosci       Date:  2007-09-01

8.  Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.

Authors:  D A Cameron; W M Gregory; A Bowman; E D Anderson; P Levack; P Forouhi; R C Leonard
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

Review 9.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

10.  Time to be BRAVE: is educating surgeons the key to unlocking the potential of randomised clinical trials in surgery? A qualitative study.

Authors:  Shelley Potter; Nicola Mills; Simon J Cawthorn; Jenny Donovan; Jane M Blazeby
Journal:  Trials       Date:  2014-03-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.